Heart failure & cardiomyopathies
Evolution of NT-proBNP During Prerandomization Screening in VICTORIA: Implications for Clinical Outcomes and Efficacy of Vericiguat
Authors' conclusion
Substantial differences occurred in the rates of cardiovascular death and heart failure hospitalization, especially in patients with a >20% change in NT-proBNP levels during screening interval.
Study context
- Population
- Patients with HFrEF and a recent worsening HF event with NT-proBNP measured during screening and at randomisationof 5050 randomised
- Participants
- 3,821 patients
- Comparison
- NT-proBNP change during 30-day screening: >20% rise or ≤20% change vs >20% reduction
- >20% reductionn = 1,600reference
- ≤20% changen = 1,412
- >20% risen = 809
- Primary endpoint
- Composite of:
- CV death
- HF hospitalization
Primary result
As reported in the abstract
CV death and HF hospitalization
Each group vs >20% reductionAdjusted hazard ratio (95% CI)
>20% rise
1.61(1.39–1.85)
≤20% change
1.33(1.17–1.51)
Further findings
Vericiguat effect on CV death and HF hospitalization by NT-proBNP change
- No relationship between NT-proBNP changes during screening and vericiguat's effect
Original publication
Evolution of NT-proBNP During Prerandomization Screening in VICTORIA: Implications for Clinical Outcomes and Efficacy of Vericiguat. Circ Heart Fail. Published 28 July 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →